Company overview
Asimov provides synthetic biology platforms like CHO Edge for high-titer, stable CHO cell line development to accelerate therapeutic production. The company offers GMP-qualified HEK293 suspension cell lines for viral vector manufacturing in cell and gene therapies. Additional tools include AAV Edge, a suite of AI models, host cells, and genetic constructs for end-to-end gene therapy development.
Asimov — Intelligent Design is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include synthetic biology, cell line development, cho edge, hek293 cell line, viral vector production.
Structured facts
- Website
- https://www.asimov.com
- Markets served
- United States & Americas
- Keywords
- synthetic biology, cell line development, cho edge, hek293 cell line, viral vector production
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What cell line development platforms does Asimov offer?
- Asimov offers CHO Edge for generating high-titer, stable CHO cell lines optimized for molecule-specific expression, and AAV Edge for gene therapy production including AI models, host cells, and genetic tools.
- Does Asimov provide GMP-compliant solutions?
- Yes, Asimov's clonal HEK293 suspension cell line is GMP-banked and qualified for viral vector production in preclinical and clinical manufacturing.
- What are Asimov's key partnerships in manufacturing?
- Asimov partners with CDMOs like Lotte Biologics for scaling CHO Edge to GMP manufacturing, Center for Breakthrough Medicines for HEK293 viral vectors, and others like Ottimo Pharma and RevOpsis for cell line development.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
